Dr. Estelamari Rodriguez, thoracic oncologist at the University of Miami’s Sylvester Comprehensive Cancer Center, joins the show to break down the latest advances in non-mutation driven and small cell lung cancer presented at the World Conference on Lung Cancer (WCLC) and how they translate into everyday clinical practice. She discusses pivotal studies including the ALCHEMIST trial exploring adjuvant therapy in ALK-fusion–positive early-stage lung cancer, PACIFIC-2 assessing concurrent immuno...
All content for Healthcare Unfiltered is the property of Chadi Nabhan and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Dr. Estelamari Rodriguez, thoracic oncologist at the University of Miami’s Sylvester Comprehensive Cancer Center, joins the show to break down the latest advances in non-mutation driven and small cell lung cancer presented at the World Conference on Lung Cancer (WCLC) and how they translate into everyday clinical practice. She discusses pivotal studies including the ALCHEMIST trial exploring adjuvant therapy in ALK-fusion–positive early-stage lung cancer, PACIFIC-2 assessing concurrent immuno...
Returning guest Jill Feldman, a prominent lung cancer survivor and patient advocate, shares her reflections on the World Conference on Lung Cancer (WCLC) from a patient’s point of view. She discusses how patients and advocates interpret complex scientific data, why attending conferences like WCLC is vital for bridging the gap between research and real-world experience, and how the dialogue between scientists and patients continues to evolve. Jill also highlights key takeaways from the meeting...
Healthcare Unfiltered
Dr. Estelamari Rodriguez, thoracic oncologist at the University of Miami’s Sylvester Comprehensive Cancer Center, joins the show to break down the latest advances in non-mutation driven and small cell lung cancer presented at the World Conference on Lung Cancer (WCLC) and how they translate into everyday clinical practice. She discusses pivotal studies including the ALCHEMIST trial exploring adjuvant therapy in ALK-fusion–positive early-stage lung cancer, PACIFIC-2 assessing concurrent immuno...
